Santiago de Compostela

Running trials

• Recruiting

  A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

  NCT07667803· Phase 3· Source

• Recruiting

  AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

  NCT07611110· Phase 3· Source

• Recruiting

  A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

  NCT07276581· Phase 2· Source

• Recruiting

  Observational Study Protocol: LIVER-R

  NCT06252753· Source

• Recruiting

  OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain

  NCT06068049· Source

• Recruiting

  PICAROS - Acalabrutinib RWE on 1L CLL in Spain

  NCT05999877· Source

• Active, not recruiting

  PASS of Paediatric Patients Initiating Selumetinib

  NCT05388370· Source

• Active, not recruiting

  A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)

  NCT03459846· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Liver and biliary tract cancer1 recruiting
• Lung cancer1 recruiting
• Obesity1 recruiting
• Prostate cancer1 recruiting
• Rheumatoid arthritis1 recruiting
• Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).

  NCT06067828· Phase 3· Source

• Completed

  Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone

  NCT04676646· Phase 4· Source

• Completed

  Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.

  NCT04642469· Phase 3· Source

• Completed

  Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction

  NCT04610892· Phase 2· Source